SWX:GALDPharmaceuticals
Is Galderma's New Restylane Lyft Data and FDA Approval Reshaping Its Competitive Edge (SWX:GALD)?
Galderma recently presented new clinical data from its Restylane and Sculptra portfolios at the American Society for Dermatologic Surgery 2025 Annual Meeting in Chicago, including results that supported the recent FDA approval of Restylane Lyft for chin augmentation in adults.
This new data not only highlights high patient satisfaction and durable results for the company’s injectable aesthetics but also addresses emerging needs among patients experiencing facial changes following...